Hormonal treatments for premenstrual syndrome

In: Drugs of Today · 1998 · vol. 34(7) , pp. 603 · doi:10.1358/dot.1998.34.7.485258 · PMID:14988760 · W2091443408
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-07 ⓘ

Treatments for premenstrual syndrome that suppress ovulation, like GnRH agonists and Danazol, are effective but may have side effects, while progesterone has not proven superior to placebo and other hormonal treatments remain controversial.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Ovarian function appears to play a fundamental role in premenstrual syndrome (PMS). Accordingly, treatment strategies designed to suppress ovulation have generally been found to be effective for treatment of menstrually related syndromes and symptoms. GnRH agonists and Danazol(R) are probably inferior to estrogen, due to their unfavorable side effects profile. In addition, it is worthwhile to emphasize that in spite of the publicity of progesterone treatment for PMS, in most well-controlled studies it has not been shown to be more effective than placebo for the treatment of these syndromes. The efficacy of hormonal treatments that do not suppress ovulation is still controversial.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-14T06:04:04.317202+00:00
unpaywall
last seen: 2026-09-28T06:20:55.906821+00:00
License: CC0 · commercial use OK